Furthermore, our recent study demonstrated that tail vein injection of small interfering RNA targeting SPARC attenuated ischemia/reperfusion-induced renal dysfunction, inflammation, fibrosis and ADAMTS1 overexpression, indicating a novel therapeutic strategy of SPARC suppression in renal disease and a role of ADAMTS1 as a mechanism of SPARC-induced renal injury [16]. This evidence concerns the gene SPARC and kidney disorder.